Pioneering research projects at the 8th Life Science Pitch Day at the IZB

A total of sixteen teams presented their innovative ideas to almost 50 investors at the Munich start-up center.

18-Jul-2023 - On July 13, 2023, the Munich Innovation and Start-up Center for Biotechnology (IZB) organized the 8th Life Science Pitch Day in cooperation with High-Tech Gründerfonds (HTGF), Leaps by Bayer, and Boehringer Ingelheim, which brought together sixteen biotech start-ups and project teams and almost ...

Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding

Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment

27-Apr-2021 - Atriva Therapeutics GmbH has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards ...

Start-up receives €24 million for the development of a potential COVID-19 treatment

EIB backs Atriva Therapeutics

22-Oct-2020 - The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement to facilitate the company’s development and clinical testing of a novel therapy treating ...

Atriva announces closing of € 8.6 million oversubscribed convertible loan

Proceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infections

12-Aug-2020 - Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new ...

Atriva Therapeutics announces first closing of series A financing round

04-Jan-2019 - Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the first closing in its ongoing series A financing round lead by Meneldor and High-Tech Gründerfonds (HTGF). The Company founders and management joined the round, also. ...

Atriva receives an additional seed financing to develop its influenza therapeutic to clinical stage

22-Sep-2017 - The next generation of Antiviral Therapies: Co-Led by Stichting Participatie Atriva and High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received a second tranche of its running seed financing in total of € 3 Mn from Dutch, German and Canadian investors, after lead compound ATR-002 ...

Atriva receives seed financing to develop its next generation influenza therapeutic

The next generation of Antiviral Therapies

08-Feb-2017 - Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into ...